DC’s Prescription Drug Excessive Pricing Act Federally Preempted
Client Alert | 1 min read | 08.03.07
In BIO et al. v. District of Columbia et al. (case no. 2006-1593, Fed. Cir. 2007), a Federal Circuit panel declares the District of Columbia’s Prescription Drug Excessive Pricing Act (“the Act”) preempted by the federal patent laws. The Act makes it unlawful for any drug manufacturer or licensee to sell or supply for sale or impose minimum resale requirements for a patented prescription drug that results in the prescription drug being sold in the District for an “excessive price”, a term not specifically defined. Instead, it provides that excessive pricing exists where the wholesale price of a patented prescription drug in the District is over 30% higher than the comparable price in any high income country in which the product is protected by patents or other exclusive marketing rights, e.g., in the United Kingdom, Germany, Canada or Australia. The Act also provides for both public and private enforcement as well as a wide array of remedies, including but not limited to, temporary, preliminary, or permanent injunctions to enjoin the sales of prescription drugs in the District at excessive prices, fines, damages, including treble damages, and attorney’s fees.
The panel notes that, while there is no express provision in the patent statute that prohibits states from regulating the price of patented goods, state law must yield to congressional enactments if it stands as an obstacle to the accomplishment and execution of the purposes and objectives of Congress. In the federal patent statute, Congress strikes a balance between rewarding innovation and providing free consumer access by placing limitations on the scope of a patentee’s exclusionary power, the duration of the patent term and the conditions for patentability. The Act attempts to shift that balance, says the panel, penalizing high prices and limiting the full exercise of the market power that derives from a patent. Thus, the District is seen as having attempted to change federal patent policy within its borders.
Insights
Client Alert | 5 min read | 08.21.26
FTC Proposes Enforcement Policy Statement on Personalized Pricing: What Businesses Need to Know
On August 19, 2026, the Federal Trade Commission (FTC) announced a proposed Enforcement Policy Statement on personalized pricing — the practice of companies using consumers’ personal data to set individualized prices, discounts, coupons, or other incentives. The proposed statement, which is open for public comment for 30 days following publication in the Federal Register, marks a major step up in the FTC’s focus on data-driven pricing strategies and puts businesses across industries on notice that undisclosed or inadequately disclosed personalized pricing will not be tolerated. Importantly, while the proposed statement is not a binding legal requirement and does not create new legal obligations, it serves as an enforcement warning that the FTC is prepared to use its existing enforcement authority under Section 5 of the FTC Act (Section 5) and is also a potential harbinger of rulemaking. Businesses that engage in — or are considering — personalized pricing should carefully assess their disclosure practices and data collection procedures against the standards articulated in this statement.
Client Alert | 7 min read | 08.19.26
CMS’s Final Rule Bans Federal Medicaid Funding for Youth Gender-Affirming Care
Client Alert | 2 min read | 08.19.26
